B-cell non-Hodgkin’s lymphomas are a diverse group of disorders with significant biological and clinical heterogeneity. Albeit several subtypes respond well to traditional therapy; high grade forms of the disease often relapse. It is imperative to discover novel therapeutics to help improve patient survival to offer patients new treatment options.I have always had a particular affinity towards understanding the intricate molecular mechanisms of apoptosis in response to targeted agents, specifically histone deacetylase inhibition. My prior work involved understanding the synergy between histone deacetylase inhibition and proteasome inhibition in patients with lymphoma. In discovering the multiple pathways activated in response to treatment by these agents, we can further understand the biology of tumor genesis and one day hope to halt or even prevent this devastating disease.